secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0000950170-25-031303
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise
--------------------------------------------------------------------------------

- Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).
- Cash, equivalents & short-term investments were $176.5M at Dec 31, 2024; plus $65.5M raised in Jan 2025.
- Phase 3 LUCIDITY trial of avexitide in PBH recruiting; topline data expected first half 2026.
- Appointed Dan Monahan as Chief Commercial Officer to lead commercialization strategy.
- R&D expenses fell to $22.9M in Q4 2024 from $44.9M in Q4 2023; SG&A fell to $17.1M from $52.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/0000950170-25-031303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/amlx-20250304.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-031303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer